ORCA Therapeutics to Present at LSX USA Congress
Amsterdam, The Netherlands – August 2025
Dr. Wenliang Dong, Ph.D., MBA, CEO of ORCA Therapeutics, will deliver a presentation at the Life Science Executive Partnering Congress, which will be held from September 16-17, 2025, at the Thomas Michael Menino Convention & Exhibition Center in Boston, USA. Dr. Dong’s presentation is scheduled for September 16, 2025, at 14:00.
The presentation will showcase ORCA Therapeutics’ innovative oncolytic immunotherapy platform and the significant partnership opportunities presented by ORCA-010, the company’s lead product that has successfully completed Phase I/IIA clinical studies in prostate cancer. Dr. Dong will highlight the company’s strategic approach to accelerating development across multiple cancer indications through collaborative partnerships.
Dr. Wenliang Dong, Chief Executive Officer of ORCA Therapeutics and presenter at the congress, expressed his enthusiasm: “We are excited to participate in this premier partnering event where innovators, investors and senior life science dealmakers connect to shape the future of healthcare. Our presentation will demonstrate how ORCA-010’s unique ability to transform ‘cold’ tumors into ‘hot’ immunologically active environments creates compelling opportunities for strategic partnerships. We look forward to engaging with potential partners who share our vision of revolutionizing cancer treatment through transformative cancer immunotherapy.”
The presentation will provide insights into ORCA’s clinical achievements, including ORCA- 010’s demonstrated safety profile and biological efficacy, as well as the company’s expansion strategy into additional cancer indications including glioblastoma and esophageal cancer. Dr. Dong will outline multiple value creation opportunities through indication expansion, combination therapies, and strategic collaborations.
The Life Science Executive Partnering Congress is dedicated to empowering innovation, accelerating investment and facilitating partnering to shape the future of healthcare, bringing together key stakeholders in the life sciences ecosystem to drive meaningful collaborations and advance breakthrough therapies.
ORCA Therapeutics is committed to advancing innovative cancer treatments and looks forward to exploring strategic partnerships that can accelerate the development and global reach of its oncolytic immunotherapy platform.
For more information about the congress, please visit the LSX website.
About ORCA Therapeutics BV
ORCA Therapeutics BV is a leader in potent neo-adjuvant immuno-oncology therapeutics, specializing in oncolytic viruses and innovative gene therapy approaches. The company is dedicated to translating cutting-edge scientific discoveries into effective therapeutic solutions, addressing unmet medical needs and improving patient outcomes globally.
For more information about our mission and ongoing projects, visit www.orca-therapeutics.com
Media Contact
Dr. Wenliang Dong, Ph.D., MBA
CEO, ORCA Therapeutics BV
Email: info@orca-therapeutics.com
Website: www.orca-therapeutics.com